AiRuiKa (camrelizumab) / CG Invites, Jiangsu Hengrui Pharma, HLB Bio Group, NPO Petrovax, Elevar Therapeutics - LARVOL DELTA

Conjunctival reactive cutaneous capillary endothelial proliferation induced by camrelizumab in an esophageal cancer patient: a case report and literature review. (PubMed, Front Oncol) - "Unlike previously reported eyelid lesions requiring excision, conservative management with topical levofloxacin resulted in complete lesion resolution within four weeks without discontinuation of systemic therapy (Naranjo score: 7). This represents the first documented case of RCCEP affecting the conjunctival mucosa. It underscores the necessity of ophthalmologic surveillance in patients receiving camrelizumab and demonstrates that topical antimicrobial therapy constitutes an effective therapeutic strategy for complicated ocular RCCEP."

Journal • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Infectious Disease • Oncology • Ophthalmology • Squamous Cell Carcinoma

Real-world effectiveness and safety of camrelizumab plus platinum and taxane as first-line treatment for advanced esophageal squamous cell carcinoma (ESMO 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world effectiveness • Real-world evidence • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Camrelizumab plus chemotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: 4-year follow-up from a phase 2 trial (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

A Randomized Controlled Trial: Cognitive Behavior Therapy for Anxiety, Depressive Symptoms and Acute Toxicities in Oligometastatic Nasopharyngeal Carcinoma Patients Receiving Anti-PD-1, Chemotherapy and Stereotactic Body Radiation Therapy (ASTRO 2026) - "All patients received anti-PD-1 antibody (tislelizumab/toripalimab/camrelizumab) plus gemcitabine-cisplatin chemotherapy every 3 weeks for 4–6 cycles, with concurrent SBRT initiated on study day 14 (day 1 = first anti-PD-1 dose). Adding CBT to anti-PD-1 antibody, chemotherapy, and SBRT significantly alleviated anxiety/depression symptoms and reduced acute toxicities (including weight loss, fatigue, insomnia, cancer-related pain, anemia and hypoalbuminemia) in oligometastatic NPC patients."

Clinical • Metastases • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

Stereotactic Body Radiotherapy Combined with PD-1 Inhibitor in Patients with Advanced Non-Small Cell Lung Cancer: A Phase II Single-Arm Trial (ASTRO 2026) - P4 | "SBRT combined with camrelizumab demonstrated favorable disease control in patients with advanced oligometastatic NSCLC, suggesting a potential clinical benefit of integrating local ablative radiotherapy with immunotherapy in this population. Treatment-related adverse events were predominantly mild to moderate and manageable, indicating an acceptable safety profile."

Clinical • Metastases • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Real-World Effectiveness of Camrelizumab Plus Rivoceranib in Unresectable Hepatocellular Carcinoma (ESMO 2026) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Hepatocellular Cancer • Oncology • Solid Tumor

Transarterial chemoembolization (TACE) combined with Camrelizumab and Apatinib versus camrelizumab and apatinib in the treatment of unresectable hepatocellular carcinoma : A multicenter, open-label, randomized trial (ESMO 2026) - No abstract available

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

A Multicenter, Randomized, Controlled Phase II Study of Camrelizumab Combined with Apatinib as Adjuvant Therapy in Patients with High Recurrence Risk After Radical Resection of Hepatocellular Carcinoma (ESMO 2026) - No abstract available

Clinical • P2 data • Hepatocellular Cancer • Oncology • Solid Tumor

Hepatic arterial infusion chemotherapy combined with donafenib and camrelizumab in the treatment of unresectable hepatocellular carcinoma with portal vein tumor thrombus: A prospective single-arm study (ESMO 2026) - No abstract available

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

First-Line Gemcitabine and Cisplatin Plus Camrelizumab and Apatinib in Nasopharyngeal Carcinoma with Liver Metastasis: Interim Analysis (ESMO 2026) - No abstract available

Clinical • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

Liposomal irinotecan Ⅱ combined with gemcitabine, cisplatin and camrelizumab in the treatment of patients with unresectable biliary tract cancer (ESMO 2026) - No abstract available

Clinical • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

Camrelizumab Plus Apatinib Combined with Gemcitabine and Oxaliplatin (GEMOX) as First-Line Treatment for Advanced Biliary Tract Cancer (BTC): A Biomarker Exploratory Phase II Trial (ESMO 2026) - No abstract available

Biomarker • Clinical • Metastases • P2 data • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

Phase 2 Trial of First-Line Camrelizumab plus Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Oral Squamous Cell Carcinoma: Outcomes and Toxicity Profile (ASTRO 2026) - "Cisplatin-based concurrent chemoradiotherapy plus concurrent and adjuvant camrelizumab as first-line treatment demonstrates substantial efficacy in nonoperative locally advanced oral squamous cell carcinoma patients, with manageable toxicity."

Clinical • Metastases • P2 data • Oncology • Oral Cancer • Squamous Cell Carcinoma • PD-L1

Consolidative Camrelizumab Following Definitive Concurrent Chemoradiotherapy In Locally Advanced Esophageal Squamous Cell Carcinoma: A Single-Arm Phase 2 Trial (ASTRO 2026) - "The PACIFIC trial demonstrated that consolidation immunotherapy with durvalumab improves progression-free survival (PFS) and overall survival (OS)in patients with unresectable, stage III non-small cell lung cancer (NSCLC) after CCRT. Consolidative camrelizumab following definitive concurrent chemoradiotherapy with IFI shows promising efficacy and manageable toxicity in patients with unresectable locally advanced ESCC."

Metastases • P2 data • Esophageal Squamous Cell Carcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Squamous Cell Carcinoma

Checkpoint Inhibition in Metastatic ESCC: Survival Outcomes and Opportunities for RT-IO Synergy (ASTRO 2026) - "Materials/ A systematic search (2015–2025) identified phase III randomized controlled trials comparing PD-1 inhibitors (pembrolizumab, nivolumab, camrelizumab, tislelizumab) with chemotherapy in advanced or metastatic ESCC. PD-1 inhibitors significantly improve OS in advanced ESCC and establish a new systemic standard. For radiation oncologists, these findings highlight the evolving role of RT—shifting from routine palliation toward strategic integration with immunotherapy. Prospective studies should evaluate optimal sequencing, dose, and field design in RT-IO approaches, aiming to maximize local control while leveraging systemic immune activation."

Checkpoint inhibition • IO biomarker • Metastases • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Final phase 2 analysis of surufatinib plus camrelizumab, nab-paclitaxel and gemcitabine in first-line metastatic pancreatic cancer (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Oncology • Pancreatic Cancer • Solid Tumor

Bipolar androgen therapy sequential rezvilutamide combined with camrelizumab for patients with mCRPC: A single-arm prospective clinical study (ESMO 2026) - No abstract available

Clinical • Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer

Camrelizumab Plus Apatinib for Locally Advanced or Metastatic Malignant Ocular Adnexal Tumors: A Multicenter, Multi-cohort, Single-arm Phase II Trial (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Ocular Melanoma • Oncology

Impact of early antibiotic exposure on efficacy of camrelizumab plus rivoceranib versus sorafenib in patients with unresectable hepatocellular carcinoma (uHCC): a sub-analysis of CARES-310. (ESMO 2026) - No abstract available

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (LARC): The phase 3 UNION trial (ESMO 2026) - No abstract available

Clinical • Metastases • P3 data • Colorectal Cancer • Oncology • Rectal Cancer • Solid Tumor

Efficacy and Safety of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone in Esophageal Cancer: A Systematic Review and Meta-Analysis (ACG 2026) - "Pooled analysis of four included RCTs demonstrated no statistically significant improvement in pathological response outcomes with Camrelizumab plus chemotherapy compared with chemotherapy alone. Major pathological response showed an RR of 1.44 (95% CI: 0.38â5.54, P=0.59), while pathological free survival outcomes were similarly non-significant. Twelve-month overall survival also did not differ significantly between groups (RR=1.07, 95% CI: 0.78â1.47, P=0.68)."

Retrospective data • Review • Esophageal Cancer • Heart Failure • Oncology

Association of Early Versus Late Time of Day Immune Checkpoint Inhibitors Administration With Survival Outcomes in Gastric and Esophageal Cancers: A Meta-Analytical Evaluation (ACG 2026) - "Eligible studies included patients with advanced gastric or esophageal cancer treated with ICIs, including nivolumab, pembrolizumab, sintilimab, camrelizumab, tislelizumab, toripalimab, and durvalumab, administered either as monotherapy or in combination with chemotherapy. A total of 702 patients were included, comprising 520 patients with gastric cancer and 182 patients with esophageal cancer. In gastric cancer, early ICI administration was associated with significantly improved OS (pooled HR, 0.61; 95% CI, 0.49â0.77) and PFS (pooled HR, 0.62; 95% CI, 0.43â0.89). In esophageal cancer, early administration was associated with improved PFS (pooled HR, 0.40; 95% CI, 0.22â0.72)."

Checkpoint inhibition • Esophageal Cancer • Gastric Cancer • Oncology • Solid Tumor

Survival in unresectable hepatocellular carcinoma: Comparison of four treatments based on patients reconstructed from Kaplan-Meier curves of randomized trials. (PubMed, World J Gastrointest Pharmacol Ther) - "Our study compared the efficacy of the main first-line treatments recommended for unresectable HCC. While we were able to rank the magnitude of efficacy across these treatments, the intrinsic limitations of our methods (primarily the reconstruction of IPD and the indirect nature of the treatment comparisons) should be borne in mind."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor

Comparison of the efficacy of transarterial chemoembolization combined with different molecular targeted agents and/or immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a systematic review and network meta-analysis. (PubMed, J Gastrointest Oncol) - "For OS, TACE + anlotinib + sintilimab (TACE + Anl + Sin), TACE + donafenib + toripalimab (TACE + Don + Tor), TACE + lenvatinib + tislelizumab (TACE + Len + Tis), TACE + sorafenib + camrelizumab (TACE + Sor + Cam), and TACE + apatinib + camrelizumab (TACE + Apa + Cam) were all significantly superior to TACE alone...For PFS, compared with TACE alone, TACE + Anl + Sin, TACE + Don + Tor, TACE + lenvatinib + pembrolizumab (TACE + Len + Pem), TACE + Len + Tis, and TACE + Apa + Cam significantly prolonged PFS...For DCR, TACE + Len + Tis showed the best performance, while TACE + atezolizumab + bevacizumab (TACE + Ate + Bev), TACE + Anl + Sin, and TACE + Apa + Cam also demonstrated relatively high DCR. Compared with TACE alone, TACE combined with MTAs and ICIs can significantly improve outcomes in patients with uHCC. TACE + Anl + Sin, TACE + Len + Tis, and TACE + Apa + Cam may be promising treatment options, although more prospective studies are needed for further validation."

Checkpoint inhibition • Journal • Retrospective data • Hepatocellular Cancer • Oncology • Solid Tumor

A phase II study of bTAE-HAIC combined with lenvatinib and camrelizumab for patients with high tumor burden hepatocellular carcinoma: The TALEM-H trial. (ASCO 2026) - P=N/A | " Forty patients with huge HCC (defined as a single tumor >10 cm or multiple tumors >15 cm in diameter) received bTAE and FOLFOX-HAIC (Oxaliplatin 85mg/m2 2h + Calcium Levofolinate 400mg/m2 2h + Fluorouracil 2400mg/m2 46h) and lenvatinib (4-8mg) once daily plus camrelizumab (200mg) Q3W... bTAE-HAIC combined with lenvatinib plus camrelizumab represents a promising first-line treatment, offering an exceptional ORR and encouraging survival outcomes for HCC patients with a high tumor burden. Baseline characteristics."

Clinical • P2 data • Hematological Disorders • Hepatocellular Cancer • Oncology • Pneumonia • Solid Tumor